Curcumin nanodisks: Formulation and characterization

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 2, 2011, Pages 162-167

  Ghosh, Mistuni ^a   Singh, Amareshwar T K ^b   Xu, Wenwei ^c   Sulchek, Todd ^c   Gordon, Leo I ^b   Ryan, Robert O ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^d CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

Apolipoprotein; Curcumin; Delivery; Nanodisk; Phospholipid

Indexed keywords

ABSORBANCE SPECTRUM; APOLIPOPROTEINS; APOPTOSIS; CURCUMIN; DELIVERY; GROWTH INHIBITION; HEPG2 CELLS; IN-VIVO; LYMPHOMA CELLS; MANTLE CELLS; MOLAR RATIO; NANO SCALE; NANOCOMPLEXES; NANODISKS; NANOSCALE SIZE; PHOSPHOLIPID BILAYER; POLYPHENOLS; SELF-QUENCHING; THERAPEUTIC APPLICATION; WATERSOLUBLE;

ANIMAL CELL CULTURE; ATOMIC FORCE MICROSCOPY; CELL DEATH; FLUORESCENCE SPECTROSCOPY; GROWTH KINETICS; NANOSTRUCTURED MATERIALS; ONCOLOGY; PHOSPHOLIPIDS; QUENCHING;

CELL CULTURE;

CURCUMIN; CURCUMIN NANODISK; NANODISC; PHOSPHOLIPID; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ATOMIC FORCE MICROSCOPY; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; FLUORESCENCE SPECTROSCOPY; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; NANOANALYSIS; PARTICLE SIZE; PHOSPHOLIPID BILAYER; PHOTOCHEMICAL QUENCHING;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DRUG CARRIERS; HEP G2 CELLS; HUMANS; NANOSTRUCTURES;

EID: 79952751215     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2010.08.002     Document Type: Article

References (25)

1. Jurenka J.S. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alternative Med Rev 2009, 14:141-153.
2. Epstein J., Sanderson I.R., Macdonald T.T. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 1994, 26:1-13.
3. Kunnumakkara A.B., Anand P., Aggarwal B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008, 269:199-225.
4. Hatcher H., Planalp R., Cho J., Torti F.M., Torti S.V. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008, 65:1631-1652.
5. Strimpakos A.S., Sharma R.A. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxidants Redox Signal 2008, 10:511-545.
6. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
7. Bisht S., Maitra A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr Drug Discov Technol 2009, 6:192-199.
8. Agrawal D.N., Mishra P.K. Curcumin and its analogues: potential anticancer agents. Med Res Rev 2010, 30:818-860.
9. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A., et al. Polymeric nanoparticle-encapsulated curcumin (″ nanocurcumin″ ): a novel strategy for human cancer therapy. J Nanobiotechnol 2007, 5:3.
10. Marczylo T.H., Verschoyle R.D., Cooke D.N., Morazzoni P., Steward W.P., Gescher A.J. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 2007, 60:171-177.
11. Narayanan N.K., Nargi D., Randolph C., Narayanan B.A. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 2009, 125:1-8.
12. Thangapazham R.L., Puri A., Tele S., Blumenthal R., Maheshwari R.K. Evaluation of a nanotechnology based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol 2008, 32:1119-1123.
13. Ryan R.O. Nanodisks: hydrophobic drug delivery vehicle. Expert Opin Drug Deliv 2008, 5:343-351.
14. Oda M.N., Hargreaves P.L., Beckstead J.A., Redmond K.A., van Antwerpen R., Ryan R.O. Reconstituted high-density lipoprotein enriched with the polyene antibiotic, amphotericin B. J Lipid Res 2006, 47:260-267.
15. Redmond K.A., Nguyen T.S., Ryan R.O. All-trans retinoic acid nanodisks. Int J Pharm 2007, 339:246-250.
16. Ryan R.O., Forte T.M., Oda M.N. Optimized bacterial expression of human apolipoprotein A-I. Protein Expr Purif 2003, 27:98-103.
17. Singh A.T.K., Evens A.M., Prachand S.N., Gordon L.I. Motexafin Gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines. Anticancer Res 2010, 30:1131-1136.
18. Singh A.T.K., Evens A.M., Anderson R.J., Beckstead J.A., Sankar N., Bhalla S., et al. All trans retinoic acid nanodisks enhance retinoic acid receptor-mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Brit J Haemotol 2010, 150:158-169.
19. Weers P.M., Narayanaswami V., Ryan R.O. Modulation of the lipid binding properties of the N-terminal domain of human apolipoprotein E3. Eur J Biochem 2001, 268:3728-3735.
20. Chignell C.F., Bilski P., Reszka K.J., Motten A.G., Sik R.H., Dahl T.A. Spectral and photochemical properties of curcumin. Photochem Photobiol 1994, 59:295-302.
21. Khopde S.M., Priyadarsini I., Palit D.K., Mukherjee T. Effect of solvent on the excited-state photophysical properties of curcumin. Photochem Photobiol 2000, 72:625-631.
22. Jasim F., Ali F. Measurement of some spectrophotometric parameters of curcumin in 12 polar and nonpolar organic solvents. Microchem J 1989, 39:156-159.
23. Nelson K.G., Bishop J.V., Ryan R.O., Titus R. Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice. Antimicrob Agents Chemother 2006, 50:1238-1244.
24. Dhillon N., Aggrawal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008, 14:4491-4499.
25. Iovannisci D.M., Beckstead J.A., Ryan R.O. Targeting nanodisks via a single chain variable antibody-apolipoprotein chimera. Biochem Biophys Res Commun 2009, 379:466-469.